Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials.
about
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trialAttainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?Improving clinical descriptions to understand the effects of dementia treatment: consensus recommendations.Biomarkers to measure treatment effects in Alzheimer's disease: what should we look for?Goal setting and attainment in Alzheimer's disease patients treated with donepezil.Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.Cognitive Test Performance in Relation to Health and Function in 12 European Countries: The SHARE StudyGlobal assessment measures for assessing efficacy in dementia drug trials.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias.Systematic review of non-pharmacologic interventions to delay functional decline in community-dwelling patients with dementia.For how long should we use symptomatic therapies to treat people with Alzheimer disease?Voices from the field: Expert reflections on mild cognitive impairment.
P2860
Q28362149-F1E5E633-7C58-4C7D-80C4-98EA6A72149DQ30477103-42AF4C13-080B-4C0D-A580-65B646538F6AQ30833736-0A004CDB-39E7-4DA1-A0B1-33FB79F1EED9Q33165693-02D9DEDA-2C0E-49AE-9AAF-8FA140BC066FQ34315588-7B09AC4A-4745-44C8-9571-E0FF79F6FDDAQ34982567-FA837EBE-BF58-4016-9624-4A814CAE5E18Q35417970-6B4E9117-C10F-4017-B3C0-4320E0465F3BQ35470044-245B15D1-8E29-4DD3-978E-D785AC83EA3FQ35748293-AE9DAF87-73F4-44D8-AF7F-25C3BFBA7702Q36135834-213FCC1F-CB0B-45C2-A4BE-6856BCF2DF37Q36806629-60913515-809A-4BD3-A756-7F92460E25D0Q37834619-FD7DECBF-AA84-48FE-AAED-F53B7B8C6881Q38101072-23DDDC25-24BB-4027-8A02-96350DD10048Q43117191-21648A2F-1B14-42D2-866B-71D928601A2DQ50736898-6C4A7FC3-F050-4122-8340-7B0AD6FBEFF4
P2860
Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Assessing the clinical importa ...... in anti-dementia drug trials.
@en
Assessing the clinical importa ...... in anti-dementia drug trials.
@nl
type
label
Assessing the clinical importa ...... in anti-dementia drug trials.
@en
Assessing the clinical importa ...... in anti-dementia drug trials.
@nl
prefLabel
Assessing the clinical importa ...... in anti-dementia drug trials.
@en
Assessing the clinical importa ...... in anti-dementia drug trials.
@nl
P356
P1433
P1476
Assessing the clinical importa ...... in anti-dementia drug trials.
@en
P2093
C MacKnight
K Rockwood
P356
10.1159/000054761
P577
2001-05-01T00:00:00Z